[5] From 2014, Hamet led a public-private $18.4 million project for Optimization of personalized therapeutic approaches in primary care entitled Optithera.
His major scientific contributions[7] are in the areas of hypertension, diabetes and cardiovascular diseases, using approaches that range from bench to the bedside of the patient.
Hamet contributed to the establishment of the role of the second messenger cGMP in signal transduction of hormones (this enzyme became later the target of Viagra); he improved the treatment of hypertension (HTN) in Canada, contributed to the research on diabetes, a field in which he is still working on identifying the genetic determinants responsible for complications and establishing the foundations of personalized medicine in Québec.
[citation needed] Hamet has received many honors, including the Harry Goldblatt Award from the American Heart Association in 1990 for his achievements in the field of hypertension.
In 2008, Hamet had the honor to be named as an Officer of the Ordre National du Québec and he received the prestigious Okamoto Award from the Japan Vascular Disease Research Foundation.